Display options
Cite
Pusceddu S, Verzoni E, Prinzi N, et al. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Ther Adv Med Oncol. 2017;9(3):183-188doi: 10.1177/1758834016683905.
Pusceddu, S., Verzoni, E., Prinzi, N., Mennitto, A., Femia, D., Grassi, P., Concas, L., Vernieri, C., Lo Russo, G., & Procopio, G. (2017). Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Therapeutic advances in medical oncology, 9(3), 183-188. https://doi.org/10.1177/1758834016683905
Pusceddu, Sara, et al. "Everolimus treatment for neuroendocrine tumors: latest results and clinical potential." Therapeutic advances in medical oncology vol. 9,3 (2017): 183-188. doi: https://doi.org/10.1177/1758834016683905
Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, Lo Russo G, Procopio G. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Ther Adv Med Oncol. 2017 Mar;9(3):183-188. doi: 10.1177/1758834016683905. Epub 2017 Jan 11. PMID: 28344663; PMCID: PMC5349426.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Med Oncol. 2017 Mar;9(3):183-188. doi: 10.1177/1758834016683905. Epub 2017 Jan 11.

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.

Therapeutic advances in medical oncology

Sara Pusceddu, Elena Verzoni, Natialie Prinzi, Alessia Mennitto, Daniela Femia, Paolo Grassi, Laura Concas, Claudio Vernieri, Giuseppe Lo Russo, Giuseppe Procopio

Affiliations

  1. Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
  2. Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20100, Milan, Italy.

PMID: 28344663 PMCID: PMC5349426 DOI: 10.1177/1758834016683905

Abstract

Neuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs. Everolimus is a direct inhibitor of this pathway, and therefore this molecule appears to be a well-grounded strategy for the treatment of NETs, capable of changing clinical practice. The efficacy and safety of everolimus was demonstrated in the RADIANT trials. In this work, we comment on the results of the RADIANT trials, and other recent key evidence from fully published clinical trials on everolimus, and we discuss the current role of everolimus in the treatment of NETs.

Keywords: RADIANT trials; everolimus; neuroendocrine tumors

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

  1. J Clin Oncol. 2008 Sep 10;26(26):4311-8 - PubMed
  2. Cancer. 2014 Aug 15;120(16):2457-63 - PubMed
  3. N Engl J Med. 2011 Feb 10;364(6):501-13 - PubMed
  4. Tumori. 2014 Nov-Dec;100(6):e286-9 - PubMed
  5. Drug Discov Today. 2014 Apr;19(4):458-68 - PubMed
  6. Tumori. 2014 Jan-Feb;100(1):e2-3 - PubMed
  7. Oncotarget. 2016 Jul 12;7(28):44841-44847 - PubMed
  8. Thorac Surg Clin. 2014 Aug;24(3):351-5 - PubMed
  9. Future Oncol. 2016 May;12 (10 ):1251-60 - PubMed
  10. Oncologist. 2013;18(1):46-53 - PubMed
  11. J Clin Oncol. 2008 Jul 10;26(20):3403-10 - PubMed
  12. Tumori. 2012 May-Jun;98 (3):394 - PubMed
  13. Lancet. 2016 Mar 5;387(10022):968-77 - PubMed
  14. Lancet. 2011 Dec 10;378(9808):2005-12 - PubMed
  15. N Engl J Med. 2011 Feb 10;364(6):514-23 - PubMed
  16. Chest. 2013 Apr;143(4):955-62 - PubMed
  17. Oncologist. 2014 Sep;19(9):966-74 - PubMed
  18. Pancreas. 2015 Mar;44(2):181-9 - PubMed
  19. Invest New Drugs. 2013 Oct;31(5):1265-74 - PubMed
  20. Endocrine. 2015 Mar;48(2):363-70 - PubMed
  21. Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):691-703 - PubMed
  22. J Clin Oncol. 2010 Jan 1;28(1):69-76 - PubMed
  23. Neuroendocrinology. 2015;102(1-2):18-25 - PubMed

Publication Types